- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 16 - Closing Remarks
As the panel discussion concludes, Peter Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Yehuda Handelsman, MD, FACP, FACE, FNLA; Maria Lopes, MD, MS; and Kari Uusinarkaus, MD, FAAFP, FNLA, share their final insights about managed care models and clinical and economic outcomes in diabetes and obesity.
Dr Dunn says that he expects challenges to accompany changes in drug formularies, and notes that all stakeholders involved in a patient’s care need to understand the importance of risk stratification, preventive measures, integrative care, and pharmacist-centric medication therapy management.
Dr Handelsman adds that society needs to focus on preventive measures and their long-term benefits.
Dr Lopes and Dr Uusinarkaus explain that there is no one-size-fits-all approach to addressing the diabetes and obesity epidemics. The panelists conclude that innovative population-based solutions that place an emphasis on prevention need to be developed by society, government, and the various stakeholders in the healthcare field.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
